Diagnostic tools for neurosyphilis: a systematic review

Gustavo Henrique Pereira Boog 1*, João Vitor Ziroldo Lopes 1, João Vitor Mahler 1, Marina Solti 1, Lucas Tokio Kawahara 1, Andre Kakinoki Teng 1, João Victor Taba Munhoz 1 and Anna S. Levin 2

Abstract

Purpose: Increasing incidences of syphilis highlight the preoccupation with the occurrence of neurosyphilis. This study aimed to understand the current diagnostic tools and their performance to detect neurosyphilis, including new technologies and the variety of existing methods.

Methods: We searched databases to select articles that reported neurosyphilis diagnostic methods and assessed their accuracy, presenting sensitivity and specificity values. Information was synthesized in tables. The risk of bias was examined using the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy recommendations.

Results: Fourteen studies were included. The main finding was a remarkable diversity of tests, which had varied purposes, techniques, and evaluation methodologies. There was no uniform criterion or gold standard to define neurosyphilis. The current basis for its diagnosis is clinical suspicion and cerebrospinal fluid analysis. There are new promising tests such as PCR tests and chemokine measurement assays.

Conclusions: The diagnosis of neurosyphilis is still a challenge, despite the variety of existing and developing tests. We believe that the multiplicity of reference standards adopted as criteria for diagnosis reveals the imprecision of the current definitions of neurosyphilis. An important next step for the scientific community is to create a universally accepted diagnostic definition for this disease.

Keywords: Neurosyphilis, Syphilis, Cerebrospinal fluid, Diagnosis, Diagnostic tests, Accuracy

Introduction

Neurosyphilis is a condition that has challenged physicians for centuries. The invasion of the Central Nervous System by Treponema pallidum subspecies pallidum can result in protean symptoms ranging from vasculitis, stroke, dementia, and meningitis to completely asymptomatic presentations [1]. Diagnostic tools have a far from ideal performance and thus a high degree of suspicion of the diagnosis is needed to properly identify the condition [2, 3]. None of the existing tests can be considered a good and applicable gold standard, and until now there is no consensus regarding diagnostic criteria for this disease [4].

The incidence of acquired syphilis has been rising in several countries [5–8]. Thus, knowledge of the performance capabilities and limitations of diagnostic tests is crucial for clinicians to properly diagnose and treat those afflicted by this morbid complication of untreated syphilis. In this respect, there are diagnostic accuracy systematic reviews that assessed certain tools. A review evaluated polymerase chain reaction (PCR) techniques and found out that their sensitivity is low compared to cerebrospinal fluid (CSF) serological assays, despite the limitation of not having a good gold standard [9].
Another study showed that CSF treponemal-specific antibody tests have a variable performance and a dependent relation to the prevalence (pre-test probability) of neurosyphilis [10]. Here we conducted a systematic review aiming to investigate the performance and limitations of all the current diagnostic tests assessed in the most recent literature.

Materials and methods
This systematic review was performed based on the Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA statement [11]. It was registered on the International Prospective Register of Systematic Reviews (PROSPERO; available from https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020181755) [12].

Search strategy
Systematic literature review based on online search in PubMed from National Center for Biotechnology (NCBI), Scientific Electronic Library Online (SciELO) and Embase databases was done on 18th April 2020. The following terms were used in the search engine for any match in articles: ((Syphilis) OR (Treponema pallidum)) AND ((Neurosyphilis) OR (Tabes Dorsalis) OR (Central Nervous System)) AND (Diagnosis). We limited the search to studies published from 2015 to 2020. Duplicates were deleted, using the Endnote (Clarivate Analytics) reference engine.

Inclusion and exclusion criteria
We selected papers that reported neurosyphilis diagnostic methods and strategies for patients with Treponema pallidum infection, regardless of the clinical presentation, that assessed their performance in comparison with a gold standard. We included only observational and diagnostic test studies. Clinical trials, reviews, case reports, research protocols, and presentations at conferences were not considered.

We excluded papers that were unpublished, inaccessible, or incomplete. If the article did not present a diagnostic method and its performance, it was also excluded from this review.

Assessment of risk of Bias
The analysis of the methodological quality of the studies was made using the recommendations of the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy [13], which is based on the QUADAS (Quality Assessment of Diagnostic Accuracy Studies) instrument [14]. This methodological quality assessment was presented as a summary figure and a graph figure. The instrument can be found in the web-only supplementary figure (Online Resource 1).

Study selection
After the deletion of duplicates, we screened the papers by title. Next, each abstract was assessed by two independent authors. The full text was evaluated for any potentially relevant study and reviewed by two authors to determine if they met the eligibility criteria. A third author was asked to analyze in case of discordance.

Data extraction
From the included articles, we used the Google Sheets application (Google INC.) to organize extracted data regarding the study design and limitations (diagnostic test study, case-control, cross-sectional, cohort); the sample characteristics (age distribution, sex, HIV-positivity), the diagnostic method used, the gold standard used, and the evaluation of performance (sensitivity and specificity values) of the test. Categorical information also was collected by two separated authors. The data organized in Google Sheets was subsequently summarized in tables.

Results
Records
Fourteen studies were included from the 1226 papers found in our initial search. The steps of our selection process are presented in Fig. 1.

Regarding the study design, ten were studies of diagnostic tests, three were cross-sectional studies, and one was case-control. Information about the articles and their sample characteristics can be seen in the web-only supplementary table (Online Resource 2).

Bias assessment
The results of the methodological assessment are described in Fig. 2, which shows the overall quality of the 14 studies included. The individual analysis for each study can be seen in Fig. 3.

Diagnostic tests and their performance
The main findings of our review with 14 studies are presented in Table 1. Gold standards used to evaluate the diagnostic methods studied varied widely. Some papers used more than one definition of neurosyphilis.

The tests assessed in the included studies were methodologically very different. We grouped them in clinical (if they contained neurological symptoms or signs), laboratory (CSF or blood), molecular (PCR techniques), and immunological (chemokines levels).

The sample characteristics were not homogeneous. Some studies included only negative or HIV-positive patients or both; only symptomatic or asymptomatic or both. Most samples were predominantly composed of
Fig. 1 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow chart, representing the selection of studies.

Fig. 2 Methodological quality graph: proportions of low, unclear, and high risk of bias of the studies included in this review, according to the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy recommendations [13].
men, and the median/mean age varied from 33 to 53 years. Information regarding characteristics of each specific study (design, year, and country of publication) and sample (sex and age distribution) is summarised in the web-only supplementary table (Online Resource 2).

Discussion

Considering the variety of tests and the incorporation of new technologies in clinical practice, we conducted this literature review aiming to understand what are the current and potential diagnostic methods for neurosyphilis and how they perform. The primary finding of our study was a remarkable diversity of tests, which had different purposes (diagnostic confirmation, screening), varied techniques (clinical signs/symptoms, serological analysis, CSF assessment), and a heterogeneous evaluation methodology (including or not HIV-positive individuals, including or not asymptomatic patients, comparing or not with controls, etc.). Most of the articles studied CSF alterations, measuring cells, proteins, treponemal and nontreponemal antibodies [16–20], or applied new immunological/biomolecular techniques [21–25]. Three papers assessed the significance of blood parameters to distinguish between NS+ and NS- [26–28], and only one considered clinical signs or symptoms in the investigation [29].

Among all the diagnostic tests for neurosyphilis, CSF-VDRL and CSF-RPR stand out. Both exams were considered as gold standards to confirm the diagnosis in most studies. However, there are important limitations to this choice: they are operator-dependent and have low sensitivity. Particularly, there are reports of groups of patients that have compatible clinical symptoms, positive treponemal test in blood and CSF, respond to penicillin treatment but still show negative CSF-VDRL/CSF-RPR [30]. This contributes to the great heterogeneity of classifications and patient selection for the studies, making it difficult to determine their biological and clinical implications.

The laboratory diagnosis is of utmost importance for NS. Currently, clinical suspicion of NS should prompt serum VDRL and FTA-ABS examination. Lumbar puncture is recommended for patients with neurological, otologic, or ocular symptoms, regardless of syphilis stage, including cases of treatment failure (patients with previous syphilis diagnosis and persistent high titer of serum VDRL despite adequate treatment) [31]. The current laboratory recommendation for NS diagnosis includes CSF analysis with non-treponemal tests such as VDRL or RPR (in the absence of CSF-VDRL), and with treponemal tests such as FTA-ABS, alongside CSF cellularity and protein levels. However, there are important limitations, as CSF non-treponemal tests are not sensitive enough and do not eliminate the possibility of NS in case of negative results [32]. On the other hand, CSF treponemal tests are more specific but less sensitive, so they do not confirm the diagnosis but can exclude it. Finally, the hypercellularity and elevated protein levels can support the diagnosis in the presence of a negative non-treponemal CSF test and warrant empiric treatment. That being said, the low sensitivity of CSF-VDRL is the most significant limitation, presenting a low negative predictive value.

Another challenge is regarding diagnosis in asymptomatic patients, investigated with usual tests for the hypothesis and diagnosis of neurosyphilis: FTA-ABS and RPR. Laboratory parameters (such as increased protein and leukocyte levels or even positive RPR) do not offer a significant statistical gain to confirm the disease, but, if not altered, they moderately reduce the individual’s chance of having neurosyphilis.

In addition to this classic analysis of the CSF, new technologies have emerged: biomolecular tests and chemokine measurement. The polymerase chain reaction (PCR) is relevant given its increased specificity - with the
Table 1  Main Results. Diagnostic methods for neurosyphilis and their performance

| Type of diagnostic method | Test | Performance (%) | Gold standard used to define neurosyphilis | Sample size (n) | HIV (+) Status (%) | Commentaries | Ref. |
|---------------------------|------|------------------|---------------------------------------------|----------------|-------------------|--------------|------|
| **Clinical**              |      |                  |                                             |                |                   |              |      |
|                           | Neurological symptoms | 46% | 33% | CSF-VDRL (+) OR CSF-VDRL (−) AND: a. CSF-WBC > 5 cells/μL OR b. CSF-protein > 450 mg/L OR c. Neurological symptoms without other known cause | 50 | 50 | 0 | 0% | Case-control study that evaluates the usefulness of TPPA as a diagnostic tool, either alone or associated with other criteria. Consider this test when there is clinical suspicion and negative CSF-VDRL. Possible selection bias due to retrospective inclusion of patients who underwent lumbar puncture. Another limitation is that some of the diagnostic tests evaluated are also included in the gold standard employed by the study, thus generating performance analysis confusion. 15 |
|                           | Neurological symptoms AND CSF-protein > 497 mg/L AND CSF-WBC > 3 cells/μL | 89% | 98% | | | | |
|                           | Neurological symptoms AND CSF-protein > 497 mg/L AND CSF-WBC > 3 cells/μL AND CSF-TPPA > 1: 160 | 92% | 40% | | | | |
| **Laboratory (CSF)** | CSF-protein > 497 mg/L | 54% | 85% | | | | 15 |
|                           | CSF-WBC > 3 cells/μL | 48% | 82% | | | | |
|                           | CSF-TPPA > 1: 160 | 90% | 84% | | | | |
|                           | CSF-TPPA ≥ 1: 80 | 95% (I) | 76% (II) | Three gold standards used: I. CSF-VDRL (+) II. T. pallidum RT-PCR (+) III. New loss of vision or hearing | 105 | 86 | 0 | 78% | | |
|                           | CSF-TPPA ≥ 1: 640 | 97% (I) | 94% (II) | | | | |
|                           |                  | 93% (III) | | | | | 15 |
|                           | Reactive CSF-FTA-ABS | 89% | 22% | ITPA index (TPPA CSF/serum ratio) > 2 AND: a. CSF-FTA-ABS (+) OR b. CSF-RPR > 1:1 OR c. CSF pleocytosis > 4 cells/μL OR d. CSF-protein > 500 mg/L OR e. Albumin quotient (CSF/serum) > 7.8 | 38 | 29 | 0 | 52% | The study correlates pleocytosis and albumin quotient with NS (+) (independent of HIV co-infection). Highlights the importance of lumbar puncture in diagnosing asymptomatic patients, especially in the HIV (+) population. There is a possible selection bias due to the high clinical suspicion in the patient’s inclusion in the study. 17 |
|                           | Reactive CSF-RPR | 21% | 97% | | | | |
|                           | Reactive CSF-  | 100% | 100% | Clinical suspicion, | 21 | 49 | 50 | Not | Compared the | |

Boog et al. BMC Infectious Diseases (2021) 21:568
Table 1 Main Results. Diagnostic methods for neurosyphilis and their performance (Continued)

| Type of diagnostic method | Test                  | Performance (%) | Gold standard used to define neurosyphilis | Sample size (n) | HIV (+) Status (%) | Commentaries | Ref. |
|---------------------------|-----------------------|-----------------|------------------------------------------|----------------|-------------------|--------------|------|
|                           |                       | Sensitivity     | Specificity                              |                |                   |              |      |
| RPR                       | Reactive CSF-USR      | 100%            | 100%                                     |                |                   |              |      |
|                           | Reactive CSF-VDRL     | 54% (I)         | 75% (I)                                  |                | 163 (*)           |              |      |
|                           | Reactive CSF-FTA-ABS  | 70% (I)         | 54% (I)                                  |                | 65 (I)            |              |      |
|                           | CSF-SYPHICHECK CK     | 62% (I)         | 57% (I)                                  |                | 145 (II)          |              |      |
|                           | CSF-SYPHICHECK CK ≥ 1:4 | 37% (I)     | 81% (I)                                  |                | 72 (II)           |              |      |
|                           | CSF-VDRL              | 85%             | 100%                                     |                |                   |              |      |
|                           | CSF-TREPSURE          | 92%             | 100%                                     |                |                   |              |      |
|                           | CSF-MAXISYPH          | 100%            | 100%                                     |                |                   |              |      |
|                           | CSF-INNO-LIA          | 92%             | 100%                                     |                |                   |              |      |
|                           | CSF-TPPA              | 83%             | 100%                                     |                |                   |              |      |

The authors mentioned CSF-VDRL as gold standard (*), but used the following definitions for the performance analysis:

1. CSF-WBC > 20 cells/μL (regardless of other variables)
2. Vision or hearing loss (regardless of other variables)

The reported performance of different treponemal tests (RPR and USR) with each other using CSF-VDRL as a standard. There was perfect qualitative agreement (kappa value = 1) between evaluated tests and VDRL; sensitivity and specificity were both 100%. These values should be understood as evidence of diagnostic equivalence between these tests and the standard (VDRL), which has its own limitations. Considering this NS definition, USR and RPR are as good as VDRL to differentiate between confirmed and suspected NS.

The study did not report HIV status and only included patients with neurological symptoms. Concludes that the specificity of CSF-SYPHICHECK with cutoff, and sensitivity without cutoff perform similar to CSF-VDRL and remarks that titers rapidly normalize after treatment. Reports impaired patient humoral response due to high prevalence of HIV coinfection. There was no comparison with healthy or control patients. Definitions used for evaluation were not justified with references and we considered them to be imprecise for test performance evaluation.

Among study limitations were the small sample size and the fact that the tests being evaluated were used as diagnostic criteria for NS (+), which increased its accuracy. Not all
### Table 1 Main Results. Diagnostic methods for neurosyphilis and their performance (Continued)

| Type of diagnostic method | Test | Performance (%) | Gold standard used to define neurosyphilis | Sample size (n) | HIV (+) Status (%) | Commentaries | Ref. |
|---------------------------|------|-----------------|--------------------------------------------|----------------|-------------------|--------------|------|
| Laboratory (blood)        |      |                 |                                            |                |                   |              |      |
|                           | RPR  | 1:4             | 77% 80%                                   | 191            | 0 0%              | Test performances were evaluated for NS (+) general detection (I OR II being the exposed values) and discriminating between confirmed (I) and probable (II), with a better accuracy being described for (I). A multivariate analysis found another biomarker, plasmatic CK-MB. The study included only HIV (−) patients with neurological symptoms, without control groups NS (−) or asymptomatic patients. RPR was used as the gold standard, which differs from most studies analyzed in this review, which used CSF-VDRL. | 21   |
|                           | TPPA | 1:2560          | 83% 83%                                   |                |                   |              |      |
|                           | RPR  | 1:2 OR TPPA ≥ 1:1280 | 96% 46%                                   | 139            | 263 0 0%          | The sample included syphilis patients with persistent RPR titles after treatment. ANS was most frequent between ages 51–60 years, and the best cutoff value was 1:16. This study recommended lumbar puncture in patients with persistent RPR titles. Study limitations: the absence of HIV (+) population; patient’s outcome was not reported. | 22   |
|                           | RPR  | ≥ 1:16          | 32% 88%                                   |                |                   |              |      |
|                           | CD4  | 350             | 75% 82%                                   | 12             | 19 0 100%         | This study has a small sample size and restricted population characteristics (only latent syphilis, HIV (+), and asymptomatic patients). Uses RPR as diagnostic criteria, possibly interfering with the reported specificity/sensitivity values. | 23   |
|                           | RPR  | 1:32 AND CD4 350 | 50% 67%                                   |                |                   |              |      |

- **I. Confirmed NS:**
  - CSF-RPR (+) OR
  - **II. Probable NS:**
    - Syphilis of any stage with:
      - a. CSF-protein > 500 mg/L OR CSF-WBC > 10 cells/μL (without another cause) AND
      - b. Signs/symptoms consistent with NS (without another cause).

- **Asymptomatic NS:**
  - a. No neurologic symptoms/signs
  - b. CSF-RPR (+) OR
  - c. WBC > 5 cells/μL
  - d. CSF-protein > 450 mg/dL
Table 1 Main Results. Diagnostic methods for neurosyphilis and their performance (Continued)

| Type of diagnostic method | Test | Performance (%) | Gold standard used to define neurosyphilis | Sample size (n) | HIV (+) Status (%) |
|----------------------------|------|------------------|---------------------------------------------|----------------|-------------------|
| Molecular                  | TP 47 PCR | 76% 87% | CSF-TPHA/FTA-ABS (+) AND a. CSF-WBC > 5–10 cells/μL OR b. CSF-VDRL/RPR (+) | 33 91 0 | Mostly positive |
|                            | POL A PCR | 70% 92% | a. CSF-WBC > 5–10 cells/μL OR b. CSF-VDRL/RPR (+) | 40 0 0 | 45% |
|                            | TPP 47 Nested PCR | 42% 97% | Mentioned CSF-VDRL as gold standard, but used the following definitions for the analysis: a. Serological reactive non-treponemal and treponemal tests AND; b. Signs/symptoms AND; c. CSF abnormalities such as VDRL (+), FTA-ABS (+), elevated WBC, elevated proteins | 40 0 0 | 45% |
|                            | CSF-CXCL13 > 256.4 pg/mL | 85% 82% | CSF-VDRL (+) AND CSF-TPPA (+) | 191 123 92 | 0% |
|                            | CSF-CXCL8 > 48.1 pg/mL | 79% 71% | Confirmed NS: CSF-VDRL (+) AND CSF-TPPA (+) | 191 123 92 | 0% |
|                            | CSF-CXCL10 > 163.1 pg/mL | 80% 69% | Presumed NS: CSF-VDRL (+), CSF-TPPA (+), AND: a. CSF-WBC > 8 cells/μL or CSF-protein > 450 mg/L without another cause OR b. Signs/symptoms consistent with NS without another cause | 191 123 92 | 0% |
|                            | CXCL8 (CSF/serum) > 10.3 | 79% 68% | Chemokine levels were useful for patient follow-up (decreased after treatment). They may change due to other inflammatory conditions and previous treatments/medications. Not useful for HIV co-infection. Control serum and CSF samples were from different individuals. | 191 123 92 | 0% |
|                            | CXCL10 (CSF/serum) > 1.02 | 86% 77% | The study is limited by the lack of clinical data about previous patient’s treatment, and by the sole inclusion of patients that underwent lumbar puncture. CXCL13 added more | 191 123 92 | 0% |
|                            | CSF-CXCL13 > 76.3 pg/mL | 50% 90% | CSF-RPR (+) | 16 87 0 | 54% |

Ref. 24 Addresses PCR as a promising technique for NS diagnosis. The majority of the patients presented with latent syphilis. Study limitations: small sample size; no differentiation between latent syphilis stages (which interferes in the differentiation between late and early NS/meningitis); patient outcome not reported.

Ref. 25 Study considerations valid only for symptomatic patients (exclusion of patients without ophthalmic and neurologic symptoms). The study tested Nested PCR in samples of patients with confirmed NS according to the gold standard used. The study describes problems with sample preservation that could affect sensitivity. CMV coinfection was a confusion factor present.

Ref. 26 The study is limited by the lack of clinical data about previous patient’s treatment, and by the sole inclusion of patients that underwent lumbar puncture. CXCL13 added more
The measurement of chemokines shows higher sensitivity values - ranging from 50 to 88% - but also maintains high specificity values - which ranged between 69 and 99%. The relevance of this technique consists in the possibility of identifying specific changes in the CNS, distinguishing infectious and non-infectious stress patterns. Additionally, considering more precise immune responses depending on the agent, the immune profile present in the CSF may allow, in the future, a diagnosis based on the chemokine profile and not agent identification or specific antibodies for it. However, being a recent and not fully explored technique, it has challenges, such as its accessibility, demanding specific ELISA kits, and, still, the need for having a well-described chemokine and cytokine CSF profile in health and different diseases.

Because current tests lack sensitivity, new research has been exploring novel CSF biomarkers and their potential to aid in the diagnosis or exclusion of NS. For instance, myeloid and microglial activation markers such as MIF (Macrophage migration inhibitory factor) and sTREM2 (soluble Triggering receptor expressed on myeloid cells 2) have been reported to be differentially expressed in the CSF of patients with NS and have emerged as promising tools for establishing a diagnosis, particularly in the setting where non-treponemal tests are negative but there is high clinical suspicion [36, 37].

Zhang et al. reported that several CSF proteins such as neurogranin, BACE1, and Tau are increased in patients with Alzheimer's Disease in comparison to those with NS, which may be useful in the setting of patients with cognitive decline and a past history of syphilis [38]. IL-10 has also been reported to be useful in increasing the likelihood of NS [39]. These findings are exciting and may provide clinicians with new biomarkers to assist in the confirmation or exclusion of NS in the future.
however, more studies in larger populations should be conducted.

Figure 4 shows a chart that summarizes the main clinical roles of different diagnostic tests for neurosyphilis.

We believe that the main finding of this review was the great diversity of diagnostic criteria to define neurosyphilis. Seven of the 14 articles admitted explicitly the non-existence of a good gold standard. It affected the secondary objective of our study, which was the accuracy assessment. With different gold standards, the sensitivity and specificity values vary in such a way that comparisons between tests in different studies are impaired.

Part of this issue stems from a lack of a precise understanding of the pathogenesis of neurosyphilis. Because the maintenance of long-term cultures of *Treponema pallidum* is a difficult technique, very few studies have investigated its interactions with CNS resident cells. There is limited knowledge about how the presence of the bacteria in the CNS is associated with a higher risk of developing active illness - as a transient invasion of the CNS has been reported in asymptomatic patients with positive nontreponemal tests in CSF [30]. Moreover, Single Nucleotide Polymorphisms in genes that transcribe proteins associated with the innate immune response, namely Toll-Like Receptors, are associated with a higher risk of developing neurosyphilis after acquiring syphilis [40]. It demonstrates that the development of NS consists of a complex interaction between the bacterial capacity of invasion of the CNS, evasion of the immune response, and host ability to clear the pathogen effectively.

Our review has limitations that should not be ignored. The most important are the restricted period of search (5 years), the lack of some sample information in the included papers (e.g. HIV status, age, and sex data), and the impossibility of performing statistical analysis or even simple comparisons with the sensitivity and specificity values (due to the heterogeneity and discrepancies of the gold standards). Furthermore, it should be considered that methodological failures in the included articles rebound indirectly in our study. There were papers in which the diagnostic test being evaluated was included in the gold standard for NS diagnosis, increasing accuracy. Some studies utilized limited or clinically unapplicable gold standards. Thus, our results of sensitivity and specificity exposed in Table 1 should be carefully interpreted, considering the gold standard used and the methodology of the original articles.

**Conclusion**

The diagnosis of neurosyphilis is still a challenge for physicians, and, despite the variety of the existing and developing techniques, clinical suspicion plays the main role. The multiplicity of gold standards adopted in the studies reveals the imprecision and the heterogeneity of the current definitions of neurosyphilis and shows that an important next step for the scientific community is to create a universal diagnostic definition for this disease. This would be a first step to be used by clinicians for a

---

**Fig. 4** Summary of the main clinical uses of diagnostic methods for neurosyphilis. CSF (cerebrospinal fluid); NS (neurosyphilis); VDRL (venereal disease research laboratory); RPR (rapid plasma reagin); FTA-ABS (fluorescent treponemal antibody absorption); CXCL (chemokine CXC ligand); MIF (macrophage migration inhibitory factor); sTREM2 (soluble triggering receptor expressed on myeloid cells 2); BACE1 (beta-site app-cleaving enzyme 1); IL-10 (interleukin 10)
better-standardized diagnosis, and by researchers for future assessment of new diagnostic tools.

**Abbreviations**
CNS: Central nervous system; NS: Neurosyphilis; ANS: Asymptomatic neurosyphilis; NS (+): Positive neurosyphilis diagnosis; NS (–): Negative neurosyphilis diagnosis; HIV: Human immunodeficiency virus; CSF: Cerebrospinal fluid; WBC: White blood cells; VDRL: Venereal disease research laboratory; RPR: Rapid plasma reagin; USR: Unheated serum reagin; TTPA: T. pallidum particle agglutination; TPHA: T. pallidum hemagglutination; FTA-ABS: Fluorescent treponemal antibody absorption; PCR: Polymerase chain reaction; RT-PCR: Reverse transcriptase polymerase chain reaction; CMV: Cytomegalovirus; CXCL: Chemokine CXC ligand; MIF: Macrophage migration inhibitory factor; sTREM2: Soluble triggering receptor expressed on myeloid cells 2; BACE1: Beta-site app-cleaving enzyme 1; IL10: Interleukin 10

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1186/s12879-021-06264-8.

**Acknowledgements**
We thank São Paulo Research Foundation (FAPESP) for the student grant for GHPB (n° 2019/18441-0).

**Authors’ contributions**
ASL contributed to the conceptualization and supervision of the study, advising all other authors. GHPB was responsible for the administration, and execution of this research project. The literature search was performed by GHPB and JVM. All authors contributed to the article selection. GHPB, JVM, JVZL, MS, LTK, and AKT collected and organized the study’s data. JVM, JVZL, MS, LTK, and AKT performed the bias risk assessment. GHPB, JVM, JVZL, and MS wrote the original draft. ASL and GHPB reviewed and edited the manuscript. All authors read and approved the final version of the manuscript.

**Funding**
This work was funded by a student grant from São Paulo Research Foundation (FAPESP, São Paulo, Brazil), grant n° 2019/18441-0. The funding source had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

**Availability of data and materials**
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**
Not applicable.

**Consent for publication**
Not applicable.

**Competing interests**
The authors declare that they have no competing interests.

**Author details**
1Facultade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
2Infection Control Department, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.

**Received: 20 April 2021 Accepted: 1 June 2021**

**Published online: 14 June 2021**

**References**
1. Marra CM. Neurosyphilis. Continuum (Minneap Minn). 2015;21(6 Neuroinfectious Disease):1714–28.
2. Davis AP, Stern J, Tantalo L, Sahi S, Holte S, Dunaway S, et al. How well do neurologic symptoms identify individuals with neurosyphilis. Clin Infect Dis. 2018;66(3):363–7.
3. Gianem KG, Ram S, Rice PA. The modern epidemic of syphilis. N Engl J Med. 2020;382(9):845–54.
4. Berger JR. Neurosyphilis. In: Aminoff MJ, Daroff RB, editors. Encyclopaedia of the neurological sciences. San Diego: Elsevier; 2003. p. 592–9. https://doi.org/10.1016/B0-12-228870-9/00404-4.
5. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2018. Atlanta: Department of Health and Human Services; 2019. https://doi.org/10.15602/cdc.79370.
6. Sptieri G, Unemo M, Márth O, Amaro-Gauci AJ. The resurgence of syphilis in high-income countries in the 2000s: a focus on Europe. Epidemiol Infect. 2019;147:e147.
7. Marques Dos Santos M, AKB L, Roncalli AG, Lima KC. Trends of syphilis in Brazil: a growth portrait of the treponemic epidemic. PLoS One. 2020;15(4):e0231029.
8. Tao Y, Chen MY, Tucker JD, Ong JJ, Tang W, Wong NS, et al. A nationwide spatiotemporal analysis of syphilis over 21 years and implications for prevention and control in China. Clin Infect Dis. 2020;70(1):136–9.
9. Marks M, Lawrence D, Kositz C, Mabey D. Diagnostic performance of PCR assays for the diagnosis of neurosyphilis: a systematic review. Sex Transm Infect. 2018;94(8):585–8. https://doi.org/10.1136/sextrans-2018-053666.
10. Harding AS, Gianem KG. The performance of cerebrospinal fluid treponemal-specific antibody tests in neurosyphilis: a systematic review. Sex Transm Dis. 2012;39(4):291–7. https://doi.org/10.1097/OLQ.0b013e31824c0e62.
11. McIntire MF, Moher D, Thomsbs BD, McGrath TA, Bossuyt PM, Clifford T, et al. Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: The PRISMA-DTA Statement. JAMA. 2018;319(4):388–96.
12. PROSPERO. International prospective register of systematic reviews [Internet]. York, UK: University of York. Available from: https://www.crd.york.ac.uk/prospero/.
13. Reitsma JB, Rutjes AWS, Bossuyt PM, Ades A, Lockey CM, Kostek C, et al. QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMJ. 2005 Dec 20;331(7516): 248–51. doi.org/10.1136/bmj.331.7516.248.
14. Whiting P, Rutjes AWS, Bossuyt PM, Kleijnen J. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews: The QUADAS Diagnostic Accuracy, 2011; 1(1):25. https://doi.org/10.1186/2047-7441-1-25.
15. Tong ML, Liu LL, Zeng YL, Zhang HL, Liu GL, Zheng WH, et al. Laboratory findings in neurosyphilis patients with epileptic seizures alone as the initial presenting symptom. Diagn Microbiol Infect Dis. 2013;75(4):377–80. https://doi.org/10.1016/j.diagmicrobio.2013.01.013.
16. Marra CM, Maxwell CL, Dunaway SB, Sahi SK, Tantalo LC. Cerebrospinal fluid Treponema pallidum particle agglutination assay for neurosyphilis diagnosis. J Clin Microbiol. 2017;55(6):1865–70. https://doi.org/10.1128/JCM.00310-17.
17. Merin V, Hahn K. Syphilis and neurosyphilis: HIV-coinfecion and value of diagnostic parameters in cerebrospinal fluid. Eur J Med Res. 2015;20(1):181. https://doi.org/10.1186/s40001-015-0175-8.
18. Versiani I, Cabral-Castro MJ, Puccinetti-Schiller M. A comparison of nontreponemal tests in cerebrospinal fluid for neurosyphilis diagnosis: equivalent detection of specific antibodies. Arq Neuropsiquiatr. 2019;77(2):91–5. https://doi.org/10.1590/0004-082220180155.
19. Ho EL, Tantalo LC, Jones T, Sahi SK, Marra CM. Point-of-care treponemal tests for neurosyphilis diagnosis. Sex Transm Dis. 2015;42(1):48–52. https://doi.org/10.1097/OLQ.0000000000000222.
20. Guerrier J, Jost H, Pillay A, Sun Y, Cox D, Notenboom R, et al. Evaluation of Treponemal serum tests performed on cerebrospinal fluid for diagnosis of Neurosyphilis. Am J Clin Pathol. 2015;143(4):479–84. https://doi.org/10.1309/AICPWSL3GRXMCQR.
21. Castro R, Águas MJ, Batista T, Araújo C, Mansinho K, Pereira FdLM. Detection of Treponema pallidum sp. pallidum DNA in cerebrospinal fluid (CSF) by two PCR techniques. J Clin Lab Anal. 2016;30(5):628–32. https://doi.org/10.1002/jcla.21913.

22. Vanhaecke C, Grange P, Benhaddou N, Blanche P, Salmon D, Parize P, et al. Clinical and Biological Characteristics of 40 Patients With Neurosyphilis and Evaluation of Treponema pallidum Nested Polymerase Chain Reaction in Cerebrospinal Fluid Samples. Clin Infect Dis. 2016;63(9):1180–6.

23. Wang C, Wu K, Yu Q, Zhang S, Gao Z, Liu Y, et al. CXCL13, CXCL10 and CXCL8 as Potential Biomarkers for the Diagnosis of Neurosyphilis Patients. Sci Rep. 2016:63569.

24. Mothapo KM, Verbeek MM, van der Velden LB, Ang CW, Koopmans PP, van der Ven A, et al. Has CXCL13 an added value in diagnosis of Neurosyphilis? J Clin Microbiol. 2015 May;53(5):1693–6. https://doi.org/10.1128/JCM.02917-14.

25. Zeng YL, Lin YQ, Zhang NN, Zou CN, Zhang HL, Peng F, et al. CXCL13 chemokine as a promising biomarker to diagnose neurosyphilis in HIV-negative patients. Springerplus. 2016;5(1):743. https://doi.org/10.1186/s40644-016-2462-4.

26. Xiao Y, Tong ML, Liu LL, Lin LR, Chen MJ, Zhang HL, et al. Novel predictors of neurosyphilis among HIV-negative syphilis patients with neurological symptoms: an observational study. BMC Infect Dis. 2017;17(1):310.

27. Cai SN, Long J, Chen C, Wan G, Lun WH. Incidence of asymptomatic neurosyphilis in serofast Chinese syphilis patients. J Clin Microbiol. 2015 May;53(5):1693–6. https://doi.org/10.1128/JCM.02917-14.

28. Lee JW, Wilck M, Venna N. Dementia due to neurosyphilis with persistently negative CSF VDRL. Neurology. 2005;65(11):1838. https://doi.org/10.1212/01.wnl.0000187082.92497.95.

29. Workowski KA, Bolan GA. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1–137. Erratum in: MMWR Recomm Rep. 2015 Aug 28;64(33):924. PMID: 26042815; PMCID: PMC5885289.

30. Larsen SA, Hambie EA, Wobig GH, Kennedy EJ. Cerebrospinal fluid serologic test for syphilis: treponemal and nontreponemal tests. In: Morisset R, Kurstak E, editors. Advances in sexually transmitted diseases. Utrecht: VNU Science Press; 1986. p. 157–62.

31. Menon PK, Kapila K, Ohri VC. Polymerase chain reaction and advances in infectious disease diagnosis. Med J Armed Forces India. 1999;55(3):229–31. https://doi.org/10.1016/S0377-1237(17)30450-1.

32. Yang S, Rothman RE. PCR-based diagnostics for infectious diseases: uses, limitations, and future applications in acute-care settings. Lancet Infect Dis. 2004;4(6):337–48. https://doi.org/10.1016/S1473-3099(04)01044-8.

33. DeBiasi RL, Tyler KL. Polymerase chain reaction in the diagnosis and management of central nervous system infections. Arch Neurol. 1999;56(10):1215–9. https://doi.org/10.1001/archneur.56.10.1215.

34. Lin L-R, Lin D-H, Tong M-L, Liu L-L, Fan J-Y, Zhu X-Z, et al. Macrophage migration inhibitory factor as a novel cerebrospinal fluid marker for neurosyphilis among HIV-negative patients. J Alzheimers Dis. 2020;77(1):313–22. https://doi.org/10.3233/JAD-200362.

35. Li W, Chang H, Wu W, Xu D, Jiang M, Gao J, et al. Increased CSF soluble TREM2 concentration in patients with neurosyphilis. Front Neurol. 2020;11:62. https://doi.org/10.3389/fneur.2020.00062.

36. Zhang M, Zhang X, Shi H, VanniceMehlen E, De Vos A, Liu S, et al. BACE1 and other Alzheimer’s-related biomarkers in cerebrospinal fluid and plasma distinguish Alzheimer’s disease patients from cognitively-impaired neurosyphilis patients. J Alzheimers Dis. 2020;77(1):313–22. https://doi.org/10.3233/JAD-200362.

37. Li W, Wu W, Chang H, Jiang M, Gao J, Xu Y, et al. Cerebrospinal fluid cytokines in patients with neurosyphilis: the significance of interleukin-10 for the disease. Biomed Res Int. 2020;2020:812671.

38. Marra CM, Saha SK, Tantalo LC, Ho EL, Dunaway SB, Jones T, et al. Toll-like receptor polymorphisms are associated with increased neurosyphilis risk. Sex Transm Dis. 2014;41(7):440–6. https://doi.org/10.1097/OLQ.0000000000000149.